Timothy H Almazan, MD
Dermatology · Cerritos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 15 years
- University of California, San Diego School of Medicine, 2011
Offices
1 location
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Almazan’s office at (562) 246-6222 to ask if they take your plan before you enroll.
California Medical Board record
Licence A125941 · Current
Licensed to practise in California · since 2013 · expires 2027-06-30 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Dermatology - Dermatology
Original Medicare doctor bills
$31,496
Medicare paid this office $31,496 for 167 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 95 | $7,163 | $64 |
| Return visit (30+ min) | 33 | $5,101 | $98 |
| New patient visit (45+ min) | 27 | $3,506 | $130 |
| Biopsy of related skin growth, first growth | 35 | $3,127 | $80 |
| New patient visit (30+ min) | 38 | $2,899 | $76 |
See all 8 services
| Short return visit (20+ min) | 95 | $7,163 | $64 |
| Return visit (30+ min) | 33 | $5,101 | $98 |
| New patient visit (45+ min) | 27 | $3,506 | $130 |
| Biopsy of related skin growth, first growth | 35 | $3,127 | $80 |
| New patient visit (30+ min) | 38 | $2,899 | $76 |
| Destruction of skin growth, 1-14 growths | 27 | $2,818 | $94 |
| Destruction of precancer skin growth, 1 growth | 34 | $1,612 | $42 |
| Destruction of precancer skin growth, 2-14 growths | 25 | $722 | $5 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 105 | More than 76% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 52 | More than 69% of doctors who do this |
Procedures year by year
| Procedure | 2014 | 2015 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | – | – | 144 | 242 | 134 |
| Destruction of precancer skin growth, 1 growth | – | – | 42 | 62 | 38 |
| Biopsy of related skin growth, first growth | – | – | 40 | 57 | 39 |
| Destruction of skin growth, 1-14 growths | – | – | 28 | 41 | 30 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | – | – | 15 | 19 | – |
| Biopsy of related skin growth, each additional growth | – | – | 20 | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
167 Original Medicare patients in 2024. Average age 74 · Women 47% · Also on Medicaid 26% · Health risk score 1.26. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 75% · Diabetes 39% · Chronic kidney disease 26% · Coronary heart disease 22% · Cancer 20% · Heart failure 19% · Depression 14% · Atrial fibrillation 13% · COPD 11% · Dementia 10%.
The office billed $113,936, Medicare allowed $45,097 and paid $31,496; for 514 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 167 | 514 | 74 | 1.26 | $113,936 | $31,496 |
| 2023 | 279 | 922 | 74 | 1.25 | $232,212 | $61,062 |
| 2022 | 212 | 604 | 75 | 1.18 | $131,269 | $43,632 |
| 2015 | 19 | 58 | 78 | 2.11 | $3,381 | $1,198 |
| 2014 | 16 | 42 | 67 | 0.98 | $2,352 | $1,195 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Short return visit (20+ min) | 136 | $13,137 | $70 |
| New patient visit (30+ min) | 99 | $7,825 | $79 |
| Return visit (30+ min) | 57 | $7,693 | $101 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 18 | $4,901 | $258 |
| New patient visit (45+ min) | 43 | $4,787 | $111 |
| Biopsy of related skin growth, first growth | 48 | $4,561 | $80 |
| Destruction of skin growth, 1-14 growths | 36 | $3,901 | $95 |
| Destruction of precancer skin growth, 1 growth | 47 | $2,738 | $44 |
| Destruction of precancer skin growth, 2-14 growths | 36 | $1,443 | $6 |
2022: 10 services
| Short return visit (20+ min) | 80 | $8,106 | $75 |
| New patient visit (30+ min) | 88 | $7,386 | $84 |
| New patient visit (45+ min) | 45 | $5,988 | $133 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 15 | $4,102 | $273 |
| Return visit (30+ min) | 25 | $3,537 | $107 |
| Biopsy of related skin growth, first growth | 37 | $3,178 | $79 |
| Destruction of skin growth, 1-14 growths | 23 | $2,875 | $103 |
| Destruction of precancer skin growth, 1 growth | 37 | $1,887 | $45 |
| Biopsy of related skin growth, each additional growth | 11 | $939 | $47 |
| Destruction of precancer skin growth, 2-14 growths | 26 | $882 | $6 |
Drugs they prescribed that Part D paid
$447,119
Pharmacies billed $447,119 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 792) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
688 generic and 104 brand-name prescriptions · $447,119 in drug cost · 25 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 54 | $217,562 | $4,029 |
| Zoryve | 14 | $11,386 | $813 |
| Clobetasol Propionate | 79 | $3,233 | $41 |
| Tacrolimus | 11 | $2,217 | $202 |
| Fluocinonide | 38 | $1,821 | $48 |
See all 19 drugs
| Dupixent | 54 | $217,562 | $4,029 |
| Zoryve | 14 | $11,386 | $813 |
| Clobetasol Propionate | 79 | $3,233 | $41 |
| Tacrolimus | 11 | $2,217 | $202 |
| Fluocinonide | 38 | $1,821 | $48 |
| Ketoconazole | 90 | $1,672 | $19 |
| Triamcinolone Acetonide | 132 | $1,443 | $11 |
| Betamethasone Diprop Augmented | 15 | $916 | $61 |
| Fluocinolone Acetonide | 11 | $835 | $76 |
| Fluorouracil | 12 | $736 | $61 |
| Clindamycin Phosphate | 22 | $682 | $31 |
| Metronidazole | 19 | $574 | $30 |
| Hydrocortisone | 69 | $501 | $7 |
| Doxycycline Hyclate | 21 | $482 | $23 |
| Hydroxyzine | 28 | $425 | $15 |
| Gabapentin | 21 | $244 | $12 |
| Prednisone | 13 | $139 | $11 |
| Ciclopirox | 15 | $136 | $9 |
| Mupirocin | 12 | $49 | $4 |
Year by year
| 2024 | 792 | 279 | 0% (0) | 13% | $447,119 |
| 2023 | 1,057 | 384 | 0% (0) | 7% | $356,281 |
| 2022 | 640 | 268 | 0% (0) | None | $107,762 |
| 2021 | 93 | 34 | None | None | $29,384 |
| 2020 | 119 | 41 | 0% (0) | None | $38,263 |
| 2019 | 86 | 45 | 0% (0) | None | $38,809 |
| 2018 | 43 | 12 | None | None | $3,000 |
| 2017 | 26 | None | None | None | $2,952 |
| 2016 | 49 | 40 | None | None | $1,760 |
| 2015 | 135 | 83 | None | 10% | $4,038 |
| 2014 | 309 | 81 | None | None | $71,161 |
| 2013 | 72 | 13 | 0% (0) | None | $9,048 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Valchlor | 13 | $152,847 | $11,757 |
| Dupixent | 17 | $74,021 | $4,354 |
| Clobetasol Propionate | 147 | $10,266 | $70 |
| Ketoconazole | 112 | $3,213 | $29 |
| Fluocinonide | 63 | $2,976 | $47 |
| Triamcinolone Acetonide | 188 | $2,790 | $15 |
| Betamethasone Diprop Augmented | 22 | $1,437 | $65 |
| Doxycycline Hyclate | 49 | $1,362 | $28 |
| Mycophenolate Mofetil | 16 | $1,254 | $78 |
| Hydrocortisone | 102 | $1,114 | $11 |
| Clindamycin Phosphate | 15 | $1,091 | $73 |
| Nyamyc | 11 | $1,067 | $97 |
| Fluorouracil | 14 | $1,051 | $75 |
| Ciclopirox | 21 | $455 | $22 |
| Metronidazole | 11 | $451 | $41 |
| Hydroxyzine | 16 | $321 | $20 |
| Gabapentin | 27 | $247 | $9 |
| Cephalexin | 15 | $198 | $13 |
| Prednisone | 14 | $125 | $9 |
| Mupirocin | 20 | $124 | $6 |
2022: 12 drugs
| Clobetasol Propionate | 67 | $6,982 | $104 |
| Ketoconazole | 61 | $2,174 | $36 |
| Triamcinolone Acetonide | 141 | $2,173 | $15 |
| Fluocinonide | 26 | $1,741 | $67 |
| Fluorouracil | 14 | $1,576 | $113 |
| Hydrocortisone | 91 | $983 | $11 |
| Clindamycin Phosphate | 11 | $838 | $76 |
| Mupirocin | 22 | $234 | $11 |
| Gabapentin | 18 | $174 | $10 |
| Prednisone | 15 | $164 | $11 |
| Cephalexin | 17 | $145 | $9 |
| Hydroxyzine | 12 | $104 | $9 |
2021: 1 drug
| Montelukast | 11 | $77 | $7 |
2020: 3 drugs
| Fluocinonide | 12 | $891 | $74 |
| Triamcinolone Acetonide | 13 | $182 | $14 |
| Prednisone | 11 | $97 | $9 |
2019: 2 drugs
| Clobetasol Propionate | 11 | $1,036 | $94 |
| Triamcinolone Acetonide | 18 | $280 | $16 |
2015: 2 drugs
| Ibuprofen | 12 | $80 | $7 |
| Prednisone | 11 | $35 | $3 |
2014: 7 drugs
| Atorvastatin | 19 | $499 | $26 |
| Metformin | 15 | $183 | $12 |
| Benazepril | 14 | $166 | $12 |
| Simvastatin | 15 | $148 | $10 |
| Metoprolol | 14 | $120 | $9 |
| Glimepiride | 14 | $104 | $7 |
| Ibuprofen | 11 | $68 | $6 |
2013: 1 drug
| Atorvastatin | 11 | $353 | $32 |
Money from drug and device companies
$1,749 in 2025
| 2025 | 15 | 80 | None | $1,749 |
| 2024 | 9 | 25 | None | $580 |
| 2023 | 10 | 34 | None | $833 |
| 2022 | 3 | 23 | None | $234 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Galderma Laboratories L.P. | Nemluvio | $316 | 16 payments
|
| Abbvie | Rinvoq | $307 | 16 payments
|
| Janssen Biotech | Tremfya | $289 | 15 payments
|
| Genzyme | Dupixent | $207 | 7 payments
|
| Pfizer | Cibinqo | $175 | 9 payments
|
| LEO Pharma | Anzupgo | $128 | 3 payments
|
See all 80 published payments
| Incyte | Meals · 2025-12-13 | Opzelura | $30 |
| Pfizer | Meals · 2025-12-12 | Cibinqo | $27 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-12-10 | Siliq | $23 |
| Abbvie | Meals · 2025-12-09 | Skyrizi | $28 |
| Abbvie | Meals · 2025-12-09 | Rinvoq | $10 |
| Genzyme | Meals · 2025-12-08 | Dupixent | $30 |
| Galderma Laboratories L.P. | Meals · 2025-12-08 | Nemluvio | $3 |
| Pfizer | Meals · 2025-12-04 | Cibinqo | $19 |
| Pfizer | Meals · 2025-12-03 | Cibinqo | $22 |
| Janssen Biotech | Meals · 2025-12-02 | Tremfya | $12 |
| Genzyme | Meals · 2025-12-01 | Dupixent | $19 |
| Almirall | Meals · 2025-12-01 | Klisyri | $25 |
| LEO Pharma | Meals · 2025-11-25 | Anzupgo | $26 |
| Galderma Laboratories L.P. | Meals · 2025-11-17 | Nemluvio | $24 |
| Abbvie | Meals · 2025-11-14 | Rinvoq | $6 |
| Regeneron Healthcare Solutions | Meals · 2025-11-06 | Dupixent | $18 |
| Janssen Biotech | Meals · 2025-10-30 | Tremfya | $13 |
| Pfizer | Meals · 2025-10-29 | Cibinqo | $22 |
| Abbvie | Meals · 2025-10-20 | Rinvoq | $11 |
| Genzyme | Meals · 2025-10-16 | Dupixent | $39 |
| Galderma Laboratories L.P. | Meals · 2025-10-16 | Nemluvio | $5 |
| Abbvie | Meals · 2025-10-15 | Rinvoq | $28 |
| Abbvie | Meals · 2025-10-03 | Rinvoq | $4 |
| Janssen Biotech | Meals · 2025-09-30 | Tremfya | $13 |
| LEO Pharma | Meals · 2025-09-30 | Anzupgo | $22 |
| Almirall | Meals · 2025-09-29 | Klisyri | $18 |
| Incyte | Meals · 2025-09-25 | Opzelura | $28 |
| Janssen Biotech | Meals · 2025-09-23 | Tremfya | $21 |
| Galderma Laboratories L.P. | Meals · 2025-09-18 | Nemluvio | $25 |
| Galderma Laboratories L.P. | Meals · 2025-09-18 | Nemluvio | $24 |
| Pfizer | Meals · 2025-09-16 | Cibinqo | $21 |
| Janssen Biotech | Meals · 2025-09-15 | Tremfya | $5 |
| Abbvie | Meals · 2025-09-15 | Rinvoq | $23 |
| Galderma Laboratories L.P. | Meals · 2025-09-09 | None | $27 |
| Lilly USA | Meals · 2025-09-08 | Taltz | $18 |
| Abbvie | Meals · 2025-09-02 | Rinvoq | $18 |
| Incyte | Meals · 2025-08-30 | Opzelura | $22 |
| Galderma Laboratories L.P. | Meals · 2025-08-28 | Nemluvio | $9 |
| Janssen Biotech | Meals · 2025-08-19 | Tremfya | $21 |
| Abbvie | Meals · 2025-08-15 | Skyrizi | $23 |
| Galderma Laboratories L.P. | Meals · 2025-08-11 | Nemluvio | $4 |
| Janssen Biotech | Meals · 2025-08-05 | Tremfya | $7 |
| Botanix SB | Meals · 2025-08-05 | Sofdra | $22 |
| Abbvie | Meals · 2025-07-29 | Rinvoq | $29 |
| Genzyme | Meals · 2025-07-28 | Dupixent | $29 |
| Pfizer | Meals · 2025-07-24 | Cibinqo | $20 |
| Janssen Biotech | Meals · 2025-07-23 | Tremfya | $7 |
| Abbvie | Meals · 2025-07-15 | Rinvoq | $22 |
| Genzyme | Meals · 2025-07-08 | Dupixent | $37 |
| Galderma Laboratories L.P. | Meals · 2025-07-01 | Nemluvio | $23 |
| Pfizer | Meals · 2025-06-27 | Cibinqo | $17 |
| Janssen Biotech | Meals · 2025-06-26 | Tremfya | $8 |
| Pfizer | Meals · 2025-06-23 | Cibinqo | $9 |
| Regeneron Healthcare Solutions | Meals · 2025-06-19 | Dupixent | $30 |
| Genzyme | Meals · 2025-06-09 | Dupixent | $8 |
| Lilly USA | Meals · 2025-06-05 | Taltz | $25 |
| Galderma Laboratories L.P. | Meals · 2025-06-02 | Nemluvio | $6 |
| Galderma Laboratories L.P. | Meals · 2025-06-02 | Nemluvio | $7 |
| Janssen Biotech | Meals · 2025-05-29 | Tremfya | $22 |
| Abbvie | Meals · 2025-05-16 | Rinvoq | $11 |
| Pfizer | Meals · 2025-05-14 | Cibinqo | $18 |
| Janssen Biotech | Meals · 2025-05-09 | Tremfya | $25 |
| Abbvie | Meals · 2025-04-24 | Rinvoq | $26 |
| Janssen Biotech | Education · 2025-04-15 | Tremfya | $69 |
| Genzyme | Meals · 2025-04-15 | Dupixent | $46 |
| Galderma Laboratories L.P. | Meals · 2025-04-10 | Nemluvio | $18 |
| Abbvie | Meals · 2025-04-04 | Rinvoq | $14 |
| Biofrontera | Meals · 2025-04-03 | None | $18 |
| Abbvie | Meals · 2025-04-02 | Skyrizi | $27 |
| Janssen Biotech | Meals · 2025-03-13 | Tremfya | $17 |
| Abbvie | Meals · 2025-03-11 | Rinvoq | $26 |
| Galderma Laboratories L.P. | Meals · 2025-03-05 | Nemluvio | $5 |
| Helsinn Therapeutics (U.S.) | Meals · 2025-01-30 | Valchlor | $14 |
| LEO Pharma | Meals · 2025-01-24 | Anzupgo | $80 |
| Galderma Laboratories L.P. | Meals · 2025-01-23 | None | $119 |
| Janssen Biotech | Meals · 2025-01-17 | Tremfya | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-17 | Sotyktu | $35 |
| Galderma Laboratories L.P. | Meals · 2025-01-13 | Nemluvio | $1 |
| Galderma Laboratories L.P. | Meals · 2025-01-13 | Nemluvio | $15 |
| Janssen Biotech | Meals · 2025-01-07 | Tremfya | $22 |
See earlier years (2024, 2023, 2022)
2024: $580
| Janssen Biotech | Tremfya | $150 | 3 payments
|
| Abbvie | Skyrizi | $140 | 11 payments
|
| Regeneron Healthcare Solutions | Dupixent | $96 | 3 payments
|
| Genzyme | Dupixent | $87 | 2 payments
|
| Lilly USA | Taltz | $34 | 2 payments
|
| Incyte | Opzelura | $23 | 1 payment
|
| Arcutis Biotherapeutics | Zoryve | $19 | 1 payment
|
| Boston Scientific | Lux-Dx Insertable Cardiac Monitor | $18 | 1 payment
|
| Pfizer | Cibinqo | $13 | 1 payment
|
2023: $833
| Genzyme | Dupixent | $195 | 8 payments
|
| Pfizer | Cibinqo | $163 | 10 payments
|
| Janssen Biotech | Tremfya | $136 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $133 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $56 | 1 payment
|
| Incyte | Opzelura | $47 | 2 payments
|
| Dermavant Sciences | Vtama | $33 | 1 payment
|
| AbbVie | Skyrizi | $32 | 1 payment
|
| Amgen | Otezla | $24 | 1 payment
|
| Arcutis Biotherapeutics | None | $15 | 1 payment
|
2022: $234
| Abbvie | Humira | $140 | 19 payments
|
| Genzyme | Dupixent | $65 | 3 payments
|
| Amgen | Otezla | $29 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1407145931
- Licence
- CA A125941California A125941: Current · expires 2027-06-30
- Trained
- University of California, San Diego School of Medicine, 2011 · 15 years ago
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Internal medicine (207R00000X); Student in a training program (390200000X)
- Mailing address
- 11900 South St Ste 118, Cerritos, CA, 90703
- NPI first listed
- 2011-04-05
- NPI last updated
- 2024-11-27
- NPI record certified
- 2024-11-27
This is when the NPI record was last certified, not a medical board exam.